Skip to main content
Erschienen in: Surgical Endoscopy 1/2021

03.02.2020 | Endoscopy

A prospective randomized controlled trial comparing simethicone, N-acetylcysteine, sodium bicarbonate and peppermint for visualization in upper gastrointestinal endoscopy

verfasst von: Prasit Mahawongkajit, Amonpon Kanlerd

Erschienen in: Surgical Endoscopy | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Early cancer detection is crucial in improving the patients’ quality of life and upper gastrointestinal endoscopy (EGD) plays a key role in this detection. Many clearing mechanisms may be applied to create good endoscopic visualizations for the upper gastrointestinal tract using mucolytic agents, antifoaming agents, proteolytic enzymes and neutralizers. The aim of this study is to compare the effects of simethicone, N-acetylcysteine (NAC), sodium bicarbonate and peppermint as pre-medications for visualization of esophagogastroduodenoscopy (EGD).

Methods

This study was a single center prospective randomized controlled trial. The patients were randomly allocated to one of four treatment groups. Group A: water; Group B: water with simethicone; Group C: water with simethicone plus NAC 600 mg; Group D: water with simethicone, NAC, sodium bicarbonate and peppermint.

Results

A total of 128 patients were enrolled and evaluated in this study. Total visibility score (TVS) of Groups A, B, C, and D were 13.4 ± 1.86, 10.5 ± 1.45, 7.15 ± 0.98 and 6.4 ± 1.43, respectively. Group D showed lower TVS than other groups. The procedural durations of Groups C and D were significantly shorter than Group A. The volume of solution for mucosal cleansing of Groups C and D was significantly lower than Groups A and B.

Conclusions

The application of simethicone plus NAC is safe, improves endoscopic visualization and requires a minimal amount of mucosal cleansing solution. The addition of sodium bicarbonate and peppermint further improved visualization for the upper and lower gastric body.
Thai Clinical Trials Registry (TCTR) with a reference number; TCTR20190501002.
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
2.
Zurück zum Zitat Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953CrossRef Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953CrossRef
4.
Zurück zum Zitat Cheung D, Menon S, Hoare J, Dhar A, Trudgill N (2016) Factors associated with upper gastrointestinal cancer occurrence after endoscopy that did not diagnose cancer. Dig Dis Sci 61(9):2674–2684CrossRef Cheung D, Menon S, Hoare J, Dhar A, Trudgill N (2016) Factors associated with upper gastrointestinal cancer occurrence after endoscopy that did not diagnose cancer. Dig Dis Sci 61(9):2674–2684CrossRef
5.
Zurück zum Zitat Jun JK, Choi KS, Lee HY et al (2017) Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology 152(6):1319–2132CrossRef Jun JK, Choi KS, Lee HY et al (2017) Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology 152(6):1319–2132CrossRef
6.
Zurück zum Zitat Busweiler LA, Wijnhoven BP, van Berge Henegouwen MI et al (2016) Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit. Br J Surg 103(13):1855–1863CrossRef Busweiler LA, Wijnhoven BP, van Berge Henegouwen MI et al (2016) Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit. Br J Surg 103(13):1855–1863CrossRef
7.
Zurück zum Zitat Veitch AM, Uedo N, Yao K, East JE (2015) Optimizing early upper gastrointestinal cancer detection at endoscopy. Nat Rev Gastroenterol Hepatol 12(11):660–667CrossRef Veitch AM, Uedo N, Yao K, East JE (2015) Optimizing early upper gastrointestinal cancer detection at endoscopy. Nat Rev Gastroenterol Hepatol 12(11):660–667CrossRef
8.
Zurück zum Zitat Sumiyama K (2017) Past and current trends in endoscopic diagnosis for early stage gastric cancer in Japan. Gastric Cancer 20(Suppl 1):20–27CrossRef Sumiyama K (2017) Past and current trends in endoscopic diagnosis for early stage gastric cancer in Japan. Gastric Cancer 20(Suppl 1):20–27CrossRef
9.
Zurück zum Zitat Chiu PWY, Uedo N, Singh R et al (2019) An Asian consensus on standards of diagnostic upper endoscopy for neoplasia. Gut 68(2):186–197CrossRef Chiu PWY, Uedo N, Singh R et al (2019) An Asian consensus on standards of diagnostic upper endoscopy for neoplasia. Gut 68(2):186–197CrossRef
10.
Zurück zum Zitat Ro TH, Mathew MA, Misra S (2015) Value of screening endoscopy in evaluation of esophageal, gastric and colon cancers. World J Gastroenterol 21(33):9693–9706CrossRef Ro TH, Mathew MA, Misra S (2015) Value of screening endoscopy in evaluation of esophageal, gastric and colon cancers. World J Gastroenterol 21(33):9693–9706CrossRef
11.
Zurück zum Zitat Yalamarthi S, Witherspoon P, McCole D, Auld CD (2004) Missed diagnoses in patients with upper gastrointestinal cancers. Endoscopy 36(10):874–879CrossRef Yalamarthi S, Witherspoon P, McCole D, Auld CD (2004) Missed diagnoses in patients with upper gastrointestinal cancers. Endoscopy 36(10):874–879CrossRef
12.
Zurück zum Zitat Raftopoulos SC, Segarajasingam DS, Burke V, Ee HC, Yusoff IF (2010) A cohort study of missed and new cancers after esophagogastroduodenoscopy. Am J Gastroenterol 105(6):1292–1297CrossRef Raftopoulos SC, Segarajasingam DS, Burke V, Ee HC, Yusoff IF (2010) A cohort study of missed and new cancers after esophagogastroduodenoscopy. Am J Gastroenterol 105(6):1292–1297CrossRef
13.
Zurück zum Zitat Telford JJ, Enns RA (2010) Endoscopic missed rates of upper gastrointestinal cancers: parallels with colonoscopy. Am J Gastroenterol 105(6):1298–1300CrossRef Telford JJ, Enns RA (2010) Endoscopic missed rates of upper gastrointestinal cancers: parallels with colonoscopy. Am J Gastroenterol 105(6):1298–1300CrossRef
14.
Zurück zum Zitat Menon S, Trudgill N (2014) How commonly is upper gastrointestinal cancer missed at endoscopy? A meta-analysis. Endosc Int Open 2(2):E46–E50CrossRef Menon S, Trudgill N (2014) How commonly is upper gastrointestinal cancer missed at endoscopy? A meta-analysis. Endosc Int Open 2(2):E46–E50CrossRef
15.
Zurück zum Zitat Pimenta-Melo AR, Monteiro-Soares M, Libânio D, Dinis-Ribeiro M (2016) Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 28(9):1041–1049CrossRef Pimenta-Melo AR, Monteiro-Soares M, Libânio D, Dinis-Ribeiro M (2016) Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 28(9):1041–1049CrossRef
16.
Zurück zum Zitat Keeratichananont S, Sobhonslidsuk A, Kitiyakara T, Achalanan N, Soonthornpun S (2010) The role of liquid simethicone in enhancing endoscopic visibility prior to esophagogastroduodenoscopy (EGD): a prospective, randomized, double-blinded, placebo-controlled trial. J Med Assoc Thail 93(8):892–897 Keeratichananont S, Sobhonslidsuk A, Kitiyakara T, Achalanan N, Soonthornpun S (2010) The role of liquid simethicone in enhancing endoscopic visibility prior to esophagogastroduodenoscopy (EGD): a prospective, randomized, double-blinded, placebo-controlled trial. J Med Assoc Thail 93(8):892–897
17.
Zurück zum Zitat Wu L, Cao Y, Liao C, Huang J, Gao F (2011) Systematic review and meta-analysis of randomized controlled trials of Simethicone for gastrointestinal endoscopic visibility. Scand J Gastroenterol 46(2):227–235CrossRef Wu L, Cao Y, Liao C, Huang J, Gao F (2011) Systematic review and meta-analysis of randomized controlled trials of Simethicone for gastrointestinal endoscopic visibility. Scand J Gastroenterol 46(2):227–235CrossRef
18.
Zurück zum Zitat Chen HW, Hsu HC, Hsieh TY, Yeh MK, Chang WK (2014) Pre-medication to improve esophagogastroduodenoscopic visibility: a meta-analysis and systemic review. Hepatogastroenterology 61(134):1642–1648PubMed Chen HW, Hsu HC, Hsieh TY, Yeh MK, Chang WK (2014) Pre-medication to improve esophagogastroduodenoscopic visibility: a meta-analysis and systemic review. Hepatogastroenterology 61(134):1642–1648PubMed
19.
Zurück zum Zitat Monrroy H, Vargas JI, Glasinovic E et al (2018) Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial. Gastrointest Endosc 87(4):986–993CrossRef Monrroy H, Vargas JI, Glasinovic E et al (2018) Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial. Gastrointest Endosc 87(4):986–993CrossRef
20.
Zurück zum Zitat Elvas L, Areia M, Brito D, Alves S, Saraiva S, Cadime AT (2017) Premedication with simethicone and N-acetylcysteine in improving visibility during upper endoscopy: a double-blind randomized trial. Endoscopy 49(2):139–145PubMed Elvas L, Areia M, Brito D, Alves S, Saraiva S, Cadime AT (2017) Premedication with simethicone and N-acetylcysteine in improving visibility during upper endoscopy: a double-blind randomized trial. Endoscopy 49(2):139–145PubMed
21.
Zurück zum Zitat Neale JR, James S, Callaghan J, Patel P (2013) Premedication with N-acetylcysteine and simethicone improves mucosal visualization during gastroscopy: a randomized, controlled, endoscopist-blinded study. Eur J Gastroenterol Hepatol 25(7):778–783CrossRef Neale JR, James S, Callaghan J, Patel P (2013) Premedication with N-acetylcysteine and simethicone improves mucosal visualization during gastroscopy: a randomized, controlled, endoscopist-blinded study. Eur J Gastroenterol Hepatol 25(7):778–783CrossRef
22.
Zurück zum Zitat Basford PJ, Brown J, Gadeke L et al (2016) A randomized controlled trial of pre-procedure simethicone and N-acetylcysteine to improve mucosal visibility during gastroscopy—NICEVIS. Endosc Int Open 4(11):E1197–E1202CrossRef Basford PJ, Brown J, Gadeke L et al (2016) A randomized controlled trial of pre-procedure simethicone and N-acetylcysteine to improve mucosal visibility during gastroscopy—NICEVIS. Endosc Int Open 4(11):E1197–E1202CrossRef
23.
Zurück zum Zitat Spinzi G, Andrealli A, Conforti FS (2018) Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy. Gastrointest Endosc 88(3):575CrossRef Spinzi G, Andrealli A, Conforti FS (2018) Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy. Gastrointest Endosc 88(3):575CrossRef
24.
Zurück zum Zitat Zhang LY, Li WY, Ji M et al (2018) Efficacy and safety of using premedication with simethicone/Pronase during upper gastrointestinal endoscopy examination with sedation: a single center, prospective, single blinded, randomized controlled trial. Dig Endosc 30(1):57–64CrossRef Zhang LY, Li WY, Ji M et al (2018) Efficacy and safety of using premedication with simethicone/Pronase during upper gastrointestinal endoscopy examination with sedation: a single center, prospective, single blinded, randomized controlled trial. Dig Endosc 30(1):57–64CrossRef
25.
Zurück zum Zitat Kim GH, Cho YK, Cha JM, Lee SY, Chung IK (2015) Effect of pronase as mucolytic agent on imaging quality of magnifying endoscopy. World J Gastroenterol 21(8):2483–2489CrossRef Kim GH, Cho YK, Cha JM, Lee SY, Chung IK (2015) Effect of pronase as mucolytic agent on imaging quality of magnifying endoscopy. World J Gastroenterol 21(8):2483–2489CrossRef
26.
Zurück zum Zitat Lee GJ, Park SJ, Kim SJ, Kim HH, Park MI, Moon W (2012) Effectiveness of premedication with pronase for visualization of the mucosa during endoscopy: a randomized, controlled trial. Clin Endosc 45(2):161–164CrossRef Lee GJ, Park SJ, Kim SJ, Kim HH, Park MI, Moon W (2012) Effectiveness of premedication with pronase for visualization of the mucosa during endoscopy: a randomized, controlled trial. Clin Endosc 45(2):161–164CrossRef
27.
Zurück zum Zitat Liu X, Guan CT, Xue LY et al (2018) Effect of premedication on lesion detection rate and visualization of the mucosa during upper gastrointestinal endoscopy: a multicenter large sample randomized controlled double-blind study. Surg Endosc 32(8):3548–3556CrossRef Liu X, Guan CT, Xue LY et al (2018) Effect of premedication on lesion detection rate and visualization of the mucosa during upper gastrointestinal endoscopy: a multicenter large sample randomized controlled double-blind study. Surg Endosc 32(8):3548–3556CrossRef
28.
Zurück zum Zitat Chang CC, Chen SH, Lin CP et al (2007) Premedication with pronase or N-acetylcysteine improves visibility during gastroendoscopy: an endoscopist-blinded, prospective, randomized study. World J Gastroenterol 13(3):444–447CrossRef Chang CC, Chen SH, Lin CP et al (2007) Premedication with pronase or N-acetylcysteine improves visibility during gastroendoscopy: an endoscopist-blinded, prospective, randomized study. World J Gastroenterol 13(3):444–447CrossRef
29.
Zurück zum Zitat Kuo CH, Sheu BS, Kao AW, Wu CH, Chuang CH (2002) A defoaming agent should be used with pronase premedication to improve visibility in upper gastrointestinal endoscopy. Endoscopy 34(7):531–534CrossRef Kuo CH, Sheu BS, Kao AW, Wu CH, Chuang CH (2002) A defoaming agent should be used with pronase premedication to improve visibility in upper gastrointestinal endoscopy. Endoscopy 34(7):531–534CrossRef
30.
Zurück zum Zitat Fujii T, Iishi H, Tatsuta M et al (1998) Effectiveness of premedication with pronase for improving visibility during gastroendoscopy: a randomized controlled trial. Gastrointest Endosc 47(5):382–387CrossRef Fujii T, Iishi H, Tatsuta M et al (1998) Effectiveness of premedication with pronase for improving visibility during gastroendoscopy: a randomized controlled trial. Gastrointest Endosc 47(5):382–387CrossRef
31.
Zurück zum Zitat Hiki N, Kurosaka H, Tatsutomi Y et al (2003) Peppermint oil reduces gastric spasm during upper endoscopy: a randomized, double-blind, double-dummy controlled trial. Gastrointest Endosc 57(4):475–482CrossRef Hiki N, Kurosaka H, Tatsutomi Y et al (2003) Peppermint oil reduces gastric spasm during upper endoscopy: a randomized, double-blind, double-dummy controlled trial. Gastrointest Endosc 57(4):475–482CrossRef
32.
Zurück zum Zitat Hikichi T, Irisawa A, Sato M et al (2011) Utility of peppermint oil for endoscopic diagnosis of gastric tumors. Fukushima J Med Sci 57(2):60–65CrossRef Hikichi T, Irisawa A, Sato M et al (2011) Utility of peppermint oil for endoscopic diagnosis of gastric tumors. Fukushima J Med Sci 57(2):60–65CrossRef
33.
Zurück zum Zitat Imagawa A, Hata H, Nakatsu M et al (2012) Peppermint oil solution is useful as an antispasmodic drug for esophagogastroduodenoscopy, especially for elderly patients. Dig Dis Sci 57(9):2379–2384CrossRef Imagawa A, Hata H, Nakatsu M et al (2012) Peppermint oil solution is useful as an antispasmodic drug for esophagogastroduodenoscopy, especially for elderly patients. Dig Dis Sci 57(9):2379–2384CrossRef
34.
Zurück zum Zitat The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002 (2003). Gastrointest Endosc 58(6 Suppl):S3–S43 The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002 (2003). Gastrointest Endosc 58(6 Suppl):S3–S43
35.
Zurück zum Zitat Woo JG, Kim TO, Kim HJ et al (2013) Determination of the optimal time for premedication with pronase, dimethylpolysiloxane, and sodium bicarbonate for upper gastrointestinal endoscopy. J Clin Gastroenterol 47(5):389–392CrossRef Woo JG, Kim TO, Kim HJ et al (2013) Determination of the optimal time for premedication with pronase, dimethylpolysiloxane, and sodium bicarbonate for upper gastrointestinal endoscopy. J Clin Gastroenterol 47(5):389–392CrossRef
Metadaten
Titel
A prospective randomized controlled trial comparing simethicone, N-acetylcysteine, sodium bicarbonate and peppermint for visualization in upper gastrointestinal endoscopy
verfasst von
Prasit Mahawongkajit
Amonpon Kanlerd
Publikationsdatum
03.02.2020
Verlag
Springer US
Erschienen in
Surgical Endoscopy / Ausgabe 1/2021
Print ISSN: 0930-2794
Elektronische ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-020-07397-8

Weitere Artikel der Ausgabe 1/2021

Surgical Endoscopy 1/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.